12/18/2018 /
The trial achieved its primary endpoint of safety and tolerability and showed OV935 was generally well tolerated.
12/14/2018 /
A round-up of the top epilepsy research news from the past month.
12/14/2018 /
RogCon and The Florey Institute of Neuroscience presented preclinical data on the company’s lead program, RC-222, an antisense oligonucleotide designed to down-regulate SCN2A.
12/14/2018 /
A retrospective study evaluating continuous electroencephalography (cEEG) of children in intensive care units (ICUs) found a higher than anticipated number of seizures.
12/13/2018 /
Three FDA-approved drugs designed to treat other conditions significantly reduced seizure-like movement in zebrafish.
12/11/2018 /
Discover the latest about what’s happening at CURE and in our community in the December 2018 CURE Update from Chief Scientific Officer, Laura Lubbers!
12/10/2018 /
Study finds the Refractory Epilepsy Screening Tool for LGS may be a valuable clinical tool in identifying patients requiring further diagnostic evaluation for LGS.
12/10/2018 /
Results from a genome-wide mega-analysis show an enrichment for monogenic epilepsy genes as well as known targets of antiepileptic drugs. Using SNP-based heritability analyses, researchers disentangle both the unique and overlapping genetic basis to seven different epilepsy subtypes.
12/10/2018 /
A history of intolerable adverse drug reactions has a large impact on the tolerability of future antiepilepsy drug regimens.
